Neurobo Pharmaceuticals Stock Market Value
| NRBO Stock | USD 2.36 0.01 0.43% |
| Symbol | Neurobo |
Neurobo Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neurobo Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurobo Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurobo Pharmaceuticals.
| 10/29/2024 |
| 11/28/2024 |
If you would invest 0.00 in Neurobo Pharmaceuticals on October 29, 2024 and sell it all today you would earn a total of 0.00 from holding Neurobo Pharmaceuticals or generate 0.0% return on investment in Neurobo Pharmaceuticals over 30 days. Neurobo Pharmaceuticals is related to or competes with Allarity Therapeutics, Virax Biolabs, Quoin Pharmaceuticals, Biodexa Pharmaceticals, Zura Bio, Phio Pharmaceuticals, and Sonnet Biotherapeutics. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal diseas... More
Neurobo Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurobo Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurobo Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 25.62 | |||
| Value At Risk | (7.34) | |||
| Potential Upside | 6.76 |
Neurobo Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurobo Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurobo Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Neurobo Pharmaceuticals historical prices to predict the future Neurobo Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (1.22) | |||
| Treynor Ratio | (0.18) |
Neurobo Pharmaceuticals Backtested Returns
Neurobo Pharmaceuticals has Sharpe Ratio of -0.12, which conveys that the firm had a -0.12% return per unit of risk over the last 3 months. Neurobo Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neurobo Pharmaceuticals' Risk Adjusted Performance of (0.06), mean deviation of 3.36, and Standard Deviation of 4.8 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 2.6, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurobo Pharmaceuticals will likely underperform. At this point, Neurobo Pharmaceuticals has a negative expected return of -0.6%. Please make sure to verify Neurobo Pharmaceuticals' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Neurobo Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.47 |
Average predictability
Neurobo Pharmaceuticals has average predictability. Overlapping area represents the amount of predictability between Neurobo Pharmaceuticals time series from 29th of October 2024 to 13th of November 2024 and 13th of November 2024 to 28th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurobo Pharmaceuticals price movement. The serial correlation of 0.47 indicates that about 47.0% of current Neurobo Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.47 | |
| Spearman Rank Test | -0.17 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Neurobo Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Neurobo Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Neurobo Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Neurobo Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Neurobo Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Neurobo Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Neurobo Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Neurobo Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Neurobo Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Neurobo Pharmaceuticals Lagged Returns
When evaluating Neurobo Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Neurobo Pharmaceuticals stock have on its future price. Neurobo Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Neurobo Pharmaceuticals autocorrelation shows the relationship between Neurobo Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Neurobo Pharmaceuticals.
Regressed Prices |
| Timeline |
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurobo Stock
| 0.88 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Neurobo Stock
| 0.87 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.7 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.48 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.42 | OPT | Opthea | PairCorr |
| 0.38 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Neurobo Pharmaceuticals Correlation, Neurobo Pharmaceuticals Volatility and Neurobo Pharmaceuticals Alpha and Beta module to complement your research on Neurobo Pharmaceuticals. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Neurobo Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.